Home › Compare › IPCIF vs DGRO

IPCIF vs DGRO: Dividend Comparison 2026

IPCIF yields 1333.33% · DGRO yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IPCIF wins by $241528700.58M in total portfolio value
10 years
IPCIF
IPCIF
● Live price
1333.33%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$241528700.61M
Annual income
$210,475,860,072,406.56
Full IPCIF calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.13%
Share price
$68.98
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$239.96
Full DGRO calculator →

Portfolio growth — IPCIF vs DGRO

📍 IPCIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPCIFDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPCIF + DGRO cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IPCIF pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPCIF
Annual income on $10K today (after 15% tax)
$113,333.33/yr
After 10yr DRIP, annual income (after tax)
$178,904,481,061,545.56/yr
DGRO
Annual income on $10K today (after 15% tax)
$181.24/yr
After 10yr DRIP, annual income (after tax)
$203.97/yr
At 15% tax rate, IPCIF beats the other by $178,904,481,061,341.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPCIF + DGRO for your $10,000?

IPCIF: 50%DGRO: 50%
100% DGRO50/50100% IPCIF
Portfolio after 10yr
$120764350.32M
Annual income
$105,237,930,036,323.27/yr
Blended yield
87.14%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPCIF buys
0
DGRO buys
0
No recent congressional trades found for IPCIF or DGRO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPCIFDGRO
Forward yield1333.33% ✓2.13%
Annual dividend / share$2.00 ✓$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$241528700.61M ✓$31.6K
Annual income after 10y$210,475,860,072,406.56 ✓$239.96
Total dividends collected$239239876.27M ✓$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: IPCIF vs DGRO ($10,000, DRIP)

YearIPCIF PortfolioIPCIF Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$144,033$133,333.33$11,293$213.22+$132.7K → IPCIF
2$1,948,924$1,794,807.89$12,730$217.32+$1.94M → IPCIF
3$24,782,219$22,696,870.86$14,326$221.10+$24.77M → IPCIF
4$296,245,945$269,728,970.81$16,098$224.56+$296.23M → IPCIF
5$3,330,378,004$3,013,394,842.54$18,064$227.74+$3330.36M → IPCIF
6$35,223,684,321$31,660,179,856.69$20,246$230.65+$35223.66M → IPCIF
7$350,636,384,108$312,947,041,885.16$22,666$233.30+$350636.36M → IPCIF
8$3,286,630,500,315$2,911,449,569,318.85$25,349$235.73+$3286630.47M → IPCIF
9$29,021,346,295,663$25,504,651,660,325.88$28,325$237.94+$29021346.27M → IPCIF
10$241,528,700,608,766$210,475,860,072,406.56$31,624$239.96+$241528700.58M → IPCIF

IPCIF vs DGRO: Complete Analysis 2026

IPCIF — Stock

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Full IPCIF Calculator →

DGRO — ETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this IPCIF vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPCIF vs SCHDIPCIF vs JEPIIPCIF vs OIPCIF vs KOIPCIF vs MAINIPCIF vs VIGIPCIF vs NOBLIPCIF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.